Abstract:Aim . To evaluate the efficacy, safety and adherence to therapy with a fixed combination of bisoprolol/perindopril in patients with arterial hypertension (AH), stable ischemic heart disease (IHD), and a history of myocardial infarction (MI) in clinical practice. Material and methods . For patients with AH and concomitant stable angina and a history of MI, the treatment with beta-blockers and renin-angiotensin-aldosterone blockers is recommended as a part of therapy to reduce the risk of death from cardiovascular complications. This study included 504 patients. At baseline, systolic and diastolic blood pressure (SBP and DBP) and heart rate (HR) were 148.9±16.7 mm Hg, 87.7±11.0 mm Hg, and 77.4±10.5 beats/min, respectively. PRIDE was a multicenter, observational, ambispective study that included patients with hypertension, stable angina and a history of myocardial infarction, taking a fixed combination of bisoprolol/perindopril. The prospective observation period was 12 weeks from the date of inclusion in the study. The primary endpoint was a change in SBP and DBP at the end of the observation. Additional parameters of antihypertensive and antianginal efficacy and adherence to therapy were assessed as secondary variables. For exploratory purposes, an analysis was performed to evaluate predictors of achieving the target values of BP and HR, as well as adherence to therapy, including a fixed combination of bisoprolol/perindopril. Results . The antihypertensive effect that was observed by the 12th week of observation was evident as a decrease in SBP and DBP by 24.9/12.2 mm Hg (p<0.001). The proportions of patients with low, moderate, or high adherence to treatment at 12 weeks were 21.7% (n=94), 25.3% (n=110), and 53.0% (n=230), respectively. The presence of grade 3 AH was a negative predictor for achieving the target BP <140/90 mmHg (odds ratio, OR, 0.11; 95% confidence interval: 0.01-0.64). Functional class III angina in the general population, patients younger than 65 years, and female patients, and grade 2 and 3 AH in male patients were factors associated with a lower likelihood of high adherence. In women, the presence of type 2 diabetes mellitus was a positive predictor for adherence to therapy. Despite the fact that 3.7% (n=18) of patients included in the study had a decrease in SBP below 120 mm Hg by week 12, no adverse events associated with such a decrease was noted, and the therapy was well tolerated by the patients. Conclusion . Treatment of patients with AH in combination with stable IHD and a history of MI with a fixed combination of bisoprolol/perindopril was associated with significant antihypertensive efficacy and improved adherence to the prescribed treatment. The presence of grade 3 AH was associated with a significant decrease in the likelihood of achieving the BP goal, while grades 2 and 3 AH and functional class III angina negatively influenced the likelihood of high adherence to therapy.

The Combination of Perindopril and Indapamide in Treatment of Essential Hypertension

Efficacy Comparison Between 5 Mg Perindopril Arginine Salt and 4 Mg Perindopril Tert-Butylamine Salt for Patients with Mild to Moderate Essential Hypertension

Efficacy and safety of a single-pill versus free combination of perindopril/indapamide/amlodipine: a multicenter, randomized, double-blind study in Chinese patients with hypertension

Multicenter Clinical Trial on Benidipine in the Treatment of Stable Angina Pectoris

Efficacy and Safety of Torasemide in Patients with Mild to Moderate Essential Hypertension

Effects of Combination Treatment with Perindopril and Losartan on Left Ventricular Remodeling and Cardiac Function in Patients with Myocardial Infarction

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Clinical efficacy of a fixed-dose combination of amlodipine/indapamide/perindopril in patients with hypertension and multiple risk factors

Efficacy and Safety of Fixed-Dose Perindopril Arginine/Amlodipine in Hypertensive Patients Not Adequately Controlled with Amlodipine 5 Mg or Perindopril Tert-Butylamine 4 Mg Monotherapy

A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension.

[The delapril-indapamide combination in treatment of arterial hypertension: practical implications in light of the new guidelines]

Effectiveness and Tolerability of Bisoprolol / Perindopril Single-Pill Combination in Patients With Arterial Hypertension, Stable Angina Pectoris and a History of Myocardial Infarction: the PRIDE Observational Study Results

Prospective study on long curative effect of perindopril and indapamide in patients with cerebrovascular diseases

Evaluation of Indapamide Sustained-Released on Antihypertensive Effect Assessed by Ambulatory Blood Pressure Monitoring

Study of the Anti-Hypertensive Efficacy and Safety of Benidipine in Patients with Essential Hypertension

Effects and Safety of Allisartan Isoproxil Combined with Amlodipine or Indapamide in Patients with Hypertension Who Failed Allisartan Monotherapy

Clinical Study on Effect of Perindopril Combined with Atorvastatin on Blood Pressure of Community Patients with Isolated Systolic Hypertension

Multicenter clinical trial on benidipine in the treatment of hypertension

Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study

Randomized, double-blind, parallel controlled,multicentre clinical trial of fixed combination of nitrendipine and atenolol in the treatment of mild to moderate essential hypertension

A18728 Combination of Amlodipine with Diuretics or Telmisartan in High-risk Hypertensive Patients